Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

238 results about "Brucella" patented technology

Brucella is a genus of Gram-negative bacteria, named after David Bruce (1855–1931). They are small (0.5 to 0.7 by 0.6 to 1.5 µm), nonencapsulated, nonmotile, facultatively intracellular coccobacilli. Brucella spp. are the cause of brucellosis, which is a zoonosis transmitted by ingesting contaminated food (such as unpasteurized milk products), direct contact with an infected animal, or inhalation of aerosols. Transmission from human to human, for example through sexual intercourse or from mother to child, is exceedingly rare, but possible. Minimum infectious exposure is between 10 and 100 organisms.

Pig breed brucella bax inhibitor-1 (BI-1) gene deletion strain and construction method and application thereof

The invention discloses a pig breed brucella bax inhibitor-1 (BI-1) gene deletion strain and a construction method and application thereof. The strain is obtained by replacing a pig breed brucella BI-1 gene with a kanamycin resistance gene, and the method includes the main steps that a pig breed brucella S2 vaccine strain genome is taken as a template, PCR amplification is conducted to obtain an upstream homologous arm and a downstream homologous arm of the BI-1 gene, the upstream homologous arm and the downstream homologous arm of the BI-1 gene and a kanamycin resistance gene fragment also obtained through PCR amplification are together cloned into a pUC18 plasmid, and a homologous recombination deletion plasmid pUC18-BI1-KanR is obtained. The plasmid is used for electrotransformation ofa pig breed brucella competent cell, and through PCR identification, an obtained positive transformant is the pig breed brucella BI-1 gene deletion strain. Compared with a wild strain, the deletion strain shows the characteristics of decreasing the growth rate, reducing colonies, increasing cell membrane permeability, enhancing cell polymerization and the like, and it is indicated that the deletion strain has the potential of serving as a brucella attenuated live vaccine.
Owner:NORTHWEST A & F UNIV

DNA loaded Brucella ghost composite vaccine

The invention discloses a DNA loaded Brucella ghost composite vaccine. The preparation method comprises following steps: introducing a suicide plasmid that contains a nucleic acid molecule encoding atemperature sensitive regulatory protein cI857, a nucleic acid molecule encoding a bacteriophage splitting protein E, and a nucleic acid molecule encoding a bacterial nuclease protein A into Brucella;utilizing a homologous recombination technology to obtain recombinant Brucella; culturing the recombinant Brucella to obtain a bacterial solution, processing the bacterial solution at a high temperature, collecting bacterial cells, and adding target DNA to obtain the DNA loaded Brucella ghost composite vaccine. The composite vaccine has following advantages: (1) the vaccine has the characteristics of bacterial ghost, compared with a conventional killed vaccine or an attenuated live vaccine, the side effect of the composite vaccine is small, the safety is high, and the protection effect is good; and (2) the bacterial ghost is a safe and effective carrier for delivering DNA vaccines, can introduce nucleic acid vaccines into antigen presenting cells, and performs high efficient expression. The composite vaccine has an important meaning for controlling the epidemic spreading of brucellosis and has a wide application range.
Owner:INNER MONGOLIA HUAXI BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products